Dianthus TherapeuticsSTU:87E 22 PB Ratio is 4.31 as of Jul. 05, 2026, which is 98% above its 10-year median of 2.18. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,230 Biotechnology companies, Dianthus Therapeutics ranks worse than 63.98% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dianthus Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dianthus Therapeutics (STU:87E) has a PB Ratio of 4.31 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dianthus Therapeutics and its competitors. This is 98% above median its historical median of 2.18. Over the past decade, Dianthus Therapeutics' PB Ratio has ranged from 0.60 to 7.11. According to the industry distribution chart, Dianthus Therapeutics ranks #787 out of 1230 companies in the Biotechnology industry, placing it in the top 64%.
Is Dianthus Therapeutics' PB Ratio too high?
Dianthus Therapeutics' current PB Ratio of 4.31 is 98% above median its 10-year median of 2.18. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 7.11. The Biotechnology industry median PB Ratio is 2.98. Dianthus Therapeutics' value of 4.31 is 44.6% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #787 out of 1230 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' PB Ratio compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #787 out of 1230 companies for PB Ratio. This places Dianthus Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.98. Dianthus Therapeutics' value of 4.31 is 44.6% above this benchmark. Historically, Dianthus Therapeutics' own PB Ratio has ranged from 0.60 to 7.11 over the past decade. While the company's 10-year median is 2.18 vs. the industry median of 2.98, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.98, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current PB Ratio of 4.31 is 44.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dianthus Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current PB Ratio is 4.31, which is 98% above median its own 10-year median of 2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current PB Ratio is 4.31, which is 98% above median its 10-year median of 2.18 and 44.6% above the Biotechnology industry median of 2.98. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current PB Ratio is 4.31 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:87E:
PB Ratio: 4.31 (98% above median its 10-year median of 2.18)
GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
Industry Position: 44.6% above the Biotechnology median (#787 of 1230)
No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for STU:87E
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:87E has been successfully added to your 
